Compare · CLDX vs ORKA
CLDX vs ORKA
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.56B, about 2.0x CLDX ($2.77B).
- Over the past year, CLDX is up 51.0% and ORKA is up 548.8% - ORKA leads by 497.8 points.
- CLDX has been more active in the news (21 items in the past 4 weeks vs 4 for ORKA).
- CLDX has more recent analyst coverage (21 ratings vs 11 for ORKA).
- Company
- Celldex Therapeutics Inc.
- Oruka Therapeutics Inc.
- Price
- $35.27-0.47%
- $92.13+0.21%
- Market cap
- $2.77B
- $5.56B
- 1M return
- +4.44%
- +12.13%
- 1Y return
- +50.98%
- +548.77%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 21
- 4
- Recent ratings
- 21
- 11
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest CLDX
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
- Celldex Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Celldex Announces Planned Transition of Chief Financial Officer
- SEC Form 4 filed by SVP & Chief Commercial Officer Lawver Teri L
- SEC Form 4 filed by SVP & GENERAL COUNSEL Jimenez Freddy A.
- SEC Form 4 filed by SVP, CHIEF MEDICAL OFFICER Young Diane C.
- SEC Form 4 filed by SVP OF REGULATORY AFFAIRS Heath-Chiozzi Margo
- SEC Form 4 filed by SVP AND CFO Martin Samuel Bates
- SEC Form 4 filed by SVP OF CORP AFFAIRS & ADMIN. Cavanaugh Sarah
- SEC Form 4 filed by SR. VP & CPDO Crowley Elizabeth
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)